The side effect profile of Semaglutide / Cyanocobalamin Injection encompasses a range of potential adverse reactions that vary in frequency, severity, and clinical significance

Semaglutide is prescribed for: Weight loss in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) Weight loss in adult patients with an initial body mass index (BMI) of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (hypertension, type 2 diabetes mellitus, or dyslipidemia) Weight loss in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity) Reducing the risk of major adverse cardiovascular events (non-fatal myocardial infarction, CV death, or non-fatal stroke) in adults with cardiovascular disease and either obesity or overweight Treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, with moderate to advanced liver fibrosis (stages F2 to F3 fibrosis) in adults Patients taking semaglutide for any of these conditions, especially weight loss, are typically suggested to maintain a low-carb and low-fat diet

At the cellular level, 5-Amino-1MQ promotes differentiation and metabolic reprogramming of precursor cells while being well-tolerated in repeated dosing studies 4
Opening Hours Monday 9:00am - 6:00pm Tuesday9:00am - 6:00pm Wednesday9:00am - 6:00pm Thursday9:00am - 6:00pm Friday 9:00am - 6:00pm Saturday9:00am - 1:00pm SundayClosed
While AOD 9604 targets your metabolism directly, GLP-1s affect appetite and insulin signaling, with no overlap between the two
It's also important to remember that if you have Leber's disease, a specific type of B12 called cyanocobalamin could be harmful to your optic nerve